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. 
Abstract 
Background: Coagulation abnormalities such as thrombosis and disseminated intravascular 
coagulation (DIC) are the major factors that play a major role in breast cancer. In the study, 
coagulation abnormalities were assessed in breast cancer patients to help the clinician in early 
detection of DIC and management of patients at different stages of breast cancer.  
Methods: 75 patients were enrolled in the study, 50 were from case group (breast cancer 
patients) and 25 were selected as control group subjects used to compare the results. All of 
these subjects undergone, General Hematological analysis i.e. differential leukocyte count 
hemoglobin,platelets count and total leukocyte count were performed on each of the samples 
collected from the subjectsand Specific Hematological analysis i.e. Activated Partial 
Thromboplastin Time (APTT), Fibrinogen Assay, Prothrombin Time (PT), D-Dimer 
Detection and Fibrin Degradation Products (FDPs). 
Results: PT was found to be comparable in patients with breast cancer when compared with 
controls. Difference between control group (II) and subjects with breast cancer (I) was non-
significant, fibrinogen level was found to be significantly increased (p < 0.01) in patients with 
different stages of breast cancer when compared with controls. FDPs were found to be 
significantly increased (p < 0.01) in patients of breast cancer when compared with control 
group. These increased levels of FDPs may be due to enhanced fibrinolysis. D-Dimers were 
also found to be significantly increased (p < 0.01) in patients with breast cancer when 
compared with controls.  
Conclusion: Patients with breast cancer were associated with compensated DIC state 
including normal PT and APTT level but increased fibrinogen and platelets count as 
compared to the controls. Detection of D-Dimers offers a differential analysis over other 
laboratory tests for DIC. 
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Introduction 
The coagulation disorders of non-
haematological malignancies can cause 
either excessive clotting and bleeding or the 
combined abnormalities of excessive 
clotting direct to utilization of coagulation 
factors and secondarily guide to excessive 
bleeding. The non-haematological 
malignancies include carcinomas e.g. breast, 
prostate, ovary, lung, stomach tumors [1,2]. 
The essential role of the coagulation 
mechanism is carried out by the coagulation 
factors, coagulation inhibitory factors and 
fibrinolytic systems [3]. A bleeding tendency 
occurs when there is a deficiency of clotting 
factors or inhibition of coagulation 
mechanism. Coagulation factors play key 
role in haemostasis. Damage to the vessel 
wall results in simultaneous activation of 
platelets and the coagulation mechanisms. 
Platelet aggregation may be sufficient to 
occlude the damaged vessels temporarily but 
it needs fibrin, generated by coagulation 
mechanism for its permanent stability[4]. 
The derivatives of cross-linked fibrin are 
known as Plasma D-dimers. Production or 
formation of D-dimers depends upon the 
fibrin degradation by plasmin and the 
concentration increase as a result of 
thrombolysis. Plasma D-dimer represents a 
significant advance over current and historical 
FDP assays for diagnosis. The major 
indicators for the detection of plasma D-
dimers are cross-linked fibrin derivatives 
devoid ofintrusion from non-cross-linked 
fibrin/fibrinogen which consequently 
recognize fibrinolysis and intravascular 
thrombosis as different from fibrinogenolysis. 
Due to high credibility of D-dimer, 
monoclonal antibodies can be used with 
plasma samples, thereby distinguishing 
fibrinolysis from fibrinogenolysis and 
advising an advantage over most usual assays 
for FDP [5]. 
The only test that directly addresses both 
plasmin generation and thrombin is D-
Dimer test [6]. The use of D-dimer test for 
diagnosis is effective and sensitive. During 
the management of DIC and thrombolytic 
therapy D-Dimer test may provide a good 
understanding of the creation and 
disbanding of fibrin in thrombotic disease 
[7]. Revealing of fragment DD, hence offers 
anexceptionallead over other laboratory tests 
for DIC, because it reports both dimensions 
of DIC [6]. 
D1C is normally characterized by 
consumption of platelets, blood clotting 
factors V and VIII, fibrinogen that may lead 
to decrease in their circulatory levels. This 
only occurs if the process is sufficiently 
acute. FDP circulatory levels also increase 
when they are produced as a result of 
secondary or compensatory fibrinolysis 
[8,9]. In about 5-10% of patients with micro 
thrombotic lesions, fibrin thrombi are 
frequently detected in micro arterioles of the 
glomeruli and might precipitate acute renal 
failure, a variety of thrombotic skin lesions 
and acute respiratory distress syndrome, 
may also occur if these thrombi occlude 
pulmonary vasculature. High levels of 
circulating fibrin complexes and FDP’s 
inhibit the action of thrombin and also stop 
platelet function, leading to continuing 
widespread bleeding tendency[10]. The D-
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dimer and FDP tests are highly effective for 
the express diagnosis of DIC [11,12]. 
Thrombosis in cancer is frequently 
migratory and involves superficial veins at 
somewhat typical positions. In the 
laboratory, indication of intravascular 
coagulation is readily found. Some have 
thrombocytopenia, indicated by increased 
level of FDP and reduction in the levels of 
fibrinogen, but these markers only 
correspond to the failure form of DIC, and a 
great volume reveals compensated or 
overcompensated DIC. Thrombocytosis is 
more common, accompanied by decrease 
adhesion, aggregation and clot renunciation 
may also be experiential [13]. 
Non-specific mechanisms i.e. damage to 
the tissue and inflammatory reaction 
mayresult in the expression of tissue factors 
(TF). The tumor may also induce the 
expression of TF due to monocytes and 
tissue macrophages or express pro-coagulant 
activity (PCA) directly, giving them the 
capacity to produce thrombin even in the 
presence of other coagulation proteins. It has 
been demonstrated that TF expression is 
elevated in breast cancer patients [14]. Aside 
from the traditional members of the 
coagulation pathway, other pro-thrombotic 
mediators have been identified in tumor 
cells and include cancer pro-coagulants (PC) 
which are cysteine protease that activate 
factor X [15]. TF mediated tumor metastasis 
may affect translation of angiogenic growth 
factors i.e. vascular endothelial growth 
factor (VEGF). TF expression may also be 
increased by hypoxic conditions that act as a 
stimulus for VEGF production [16]. 
The APTT and PT may be expanded or 
reduced; hyperfibrinogenemia is common but 
acquired dysfibrinogenemia is rare unless the 
liver is involved. Cancer patients may have 
shortened euglobulin clot, decreased 
plasminogen levels, increase in plasmin-
antiplasmin complexes and lysis time 
because of the co-occurrence of 
intravascular activation of coagulation and 
fibrinolysis. Most cancer patients having 
complications by sudden DIC have increased 
levels of FDP. Probability of amplified FDP is 
higher in cases with inaccessible metastases, 
matched to cancer confined to a small area 
and may have predictiverates. Plasma 
fibrinopeptide A (FpA) is prominent in most 
cases with malignant disease, and serial 
measurements may reflect tumor succession 
or reaction to management process [13]. 
Fibrinogenolysis and fibrinolysis cause the 
dissolution of circulating or precipitated 
fibrinogen and fibrin. Plasminogen is 
converted to plasmin, which is then able by 
hydrolysis to cleave portions of factors V 
and VIII, fibrinogen and fibrin, when in 
excess, this process creates hypocoagulable 
state. Fibrinogen and fibrin give up their 
respective degradation products FDPs and 
D-dimers [17]. 
Cancer patients may also suffer from the 
impediment of hemolytic uremic syndrome 
or thrombotic thrombocytopenic purpura 
(HUS/TTP). Renal failure, micro-
angiopathic hemolytic anemia and severe 
thrombocytopenia should be considered 
significant indications in the characterization 
of HUS/TTP. Pulmonary symptoms i.e. 
edema in lungs is a regularexamination. 
Disorders regarding nervous system are also 
often observed. The hemolysis can be 
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gigantic and is because of red cell 
disintegration as schistocytes are observed 
in every case [18]. Patients with malignancy 
associated with DIC, DVT and 
thrombocytopenia suffers from hemostatic 
abnormalities [19]. 
The increased coagulable condition or 
"hypercoagulable state" of malignancy is 
because of a multifacetedinterface of 
abnormal cells and their products with host 
cells; escorting to diverseextent of 
mutilation of the common defense system 
that usually guards the host in opposition to 
thrombogenesis. Uncontrolled cells can 
stimulate procoagulant properties and 
restrain anticoagulant properties of platelets 
monocytes, macrophages and vascular 
endothelial cells or can trigger straight 
forwardly the blood clotting mechanism and 
resultin thrombosis. The pathophysiological 
local systematic findings collectively made 
make cancer conceivably the paramount 
illustration of "acquired thrombophilia” 
[3,8].  
In this study, main aims were to assess the 
coagulation abnormalities in patients of breast 
cancer and to help the clinician in early 
detection of DIC and management of patients 
at different stages of breast cancer. 
Methods 
Patients 
For the study subjects were selected from, 
Institute of Nuclear Medicine and Oncology 
(INMOL) and Mayo Hospital, Lahore. Total 
75 subjects were included in the study. The 
selected subjects were divided into two 
groups. Group I (case group) Inclusion 
Criteria: It included 50 breast cancer 
patients, all patients with breast cancer and 
patients without the personal and family 
history of bleeding diathesis. Exclusion 
Criteria: Patients with all hematological 
malignancies (leukemia, lymphoma, 
multiple myeloma), family history of 
bleeding diathesis, liver disease, 
hypertension, diabetes mellitus, renal 
disease and patients having history of 
chemotherapy and radiotherapy. Group II 
(control group): It included 25 healthy 
subjects with age, sex and socio-
economically matched controls from 
hospital staff or relative of the patients. They 
did not have any history of liver disease, 
diabetes mellitus or bleeding diathesis. 
Laboratory Investigations 
The blood samples were analyzed for 
general haematological investigations and 
coagulation profile. General Hematological 
Investigations: Hemoglobin, total leukocyte 
count, differential leukocyte count, platelets 
count are performed on the samples 
collected from the subjects. Specific 
Hematological investigations: PT, APTT, 
Fibrinogen Assay, FDPs, D-Dimer 
Detection was also done for collected 
samples. 
Methodology 
Data was managed and analyzed by using 
statistical software packages for social 
sciences (SPSS). For categorical variables, 
different codes were assign to 
them.Arithmetic mean (x), Standard 
Deviation (SD), Students t-test and 
Probability Value (P value) analysis was 
performed.  
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Results 
General Laboratory Investigations: In control 
group, the mean ± SD value of Hb was 12.78 
± 1.02 with a range of 11.5 – 14.3 g/dl and in 
subjects with breast cancer, the mean ± SD 
value of Hb was 11.82 ± 1.67 with a range of 
5.2 – 15.3g/dl. On comparison between group 
II and group I, subjects with breast cancer 
showed decreased Hb level and the difference 
was greatly significant (p < 0.01) statistically.  
The mean ± SD values of TLC in controls 
was 7.91 ± 1.46 with a range of 4.5 – 10.2 x 
109/L and in subjects with breast cancer was 
7.34 ± 2.15  with a range of 3.4 – 13.3 x 
109/L statistically. The comparison between 
group II and I was non-significant.The mean 
± SD values of platelet count in control 
group (II) was 227.12 ± 48.44 with range of 
154 – 329 x 109/L and in subjects with 
breast cancer (I), 256.12 ± 91.65 with a 
range of 138 – 529 x 109/L. When 
comparing these groups, Group I showed 
increased platelets count and difference was 
significant (P < 0.05) statistically. Special 
Laboratory Investigations: The mean ± SD 
values of PT in control group (II) was 12.8 ± 
1.27 with range of 11 – 15 seconds and in 
group I (subjects with breast cancer) was 
14.20 ± 1.30 with a range of 12 – 17 
seconds. On comparison with control (II) PT 
was comparable in patients with breast 
cancer (Group I). The mean ± SD values of 
APTT in control group (II) was 24.80  ±  1.38  
with range of 21 – 27 seconds and in Group I 
(subject with breast cancer) was 25.90  ± 2.90 
with a range of 21 – 32 seconds. When 
comparing with control, difference was non-
significant.The mean ± SD values of 
fibrinogen in control group (II) was 276.00 
± 43.49 with a range of 210 – 350 mg/dl and 
in patients with breast cancer (I) was 372.40 
± 106.83 with range of 140 – 520 mg/dl. 
Comparison with control group showed 
increased levels of fibrinogen in patients 
with breast cancer and difference was highly 
significant statistically (p < 0.01). 
In this study, control group (II) had 
100% FDP levels in the range of < 5 µg/ml. 
In group I (patients with breast cancer), 15 
out of 50 subjects (30%) had FDP levels of 
> 10  40 µg/ml, 28 out of 50 subjects 
(56%) had levels in the range of  40 µg/ml 
while only 7 out of 50 subjects (14%) had < 
5 µg/ml. The FDP levels were found to be 
increased in subjects with breast cancer 
(Group I) as compared with control group 
(II) and the difference was statistically 
highly significant (p < 0.01). D-Dimers in 
all control group subjects were in the range 
of < 250 ng/ml. In patients with breast 
cancer (Group I), 29 out of 50 subjects 
(58%) had D-Dimer level in the range of 
250 – 500 ng/ml, 12 out of 50 (24%) had 
levels in the range of 500 – 1000  µg/ml, 08 
out of 50 (16%) had levels in the range of 
1000 – 2000 ng/ml and only 01 out of 50 
(02%) had levels in the range of < 250 
ng/ml. D-Dimers level was found to be 
increased in subjects with breast cancer 
(Group I) as compared with control group 
(II) and difference was highly significant (p 
<0.01) statistically.Histopathological Types 
in Patients with breast Cancer:45(90%) 
patients had invasive ductal carcinoma while 
3(6%) have invasive lobular carcinoma, 
1(2%) has mucinous and 1(2%) papillary 
carcinoma. So this study shows that invasive 
ductal carcinoma is the most common type 
of breast cancer. 
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FDPs in different stages of breast 
cancer: Out of 50 cases 7 (14%) cases had 
FDPs levels <5g/ml i.e., 3(6%) subjects 
with stage II and (8%), means 4 patients 
were in stage III. 15(30%). Out of 50 
patients having breast cancer, only 1 (2%)  
case had D-dimer level <250ng/ml and 30 
(60%) patients have D-dimers level 250-
500ng/ml with 6 (18%) in stage II and 
3(6%) in stage IV. 11(22%) patients having 
D-dimers level 500-1000ng/ml with 6(12%) 
in stage III and 5(10%) in stage IV. 8(16%) 
patients having breast cancer had D-dimers 
level 1000-2000ng/ml with 1(2%) in stage 
III and 7(14%) in stage IV.When specificity 
of FDPs and D-dimers wascompared, D-
dimers were found to be more specific test 
in the detection of coagulation abnormalities 
in breast cancer patients because out of 
7(14%) patients with normal range of FDPs 
i.e., <5g/ml in stage II and III had raised 
levels of D-dimers (250-500ng/ml) in 
6(12%) cases. 
Discussion 
During the study Hb was found to be 
slightly lower in subjects with breast cancer 
as compared to control group (II) and 
difference was significant statistically. This 
decreased Hb may be due to the hemolytic 
process going on during the shedding of 
cells from the primary tumor and causing 
DIC. The findings are in agreement with that 
of [13] who also observed low Hb levels in 
subjects suffering from breast cancer. TLC 
in this study was found to be lower in 
subjects with breast cancer when compared 
with controls though it was non-significant 
statistically. Platelet count was found to be 
significantly higher (p < 0.05) in subject 
with breast cancer cases when compared 
with control group. This increased platelet 
count in breast cancer patients may be due to 
over compensated DIC. These results are in 
consistent with the findings of a pervious 
study [20] in which these changes were 
observed in breast cancer patients.PT was 
found to be comparable in patients with 
breast cancer when compared with controls. 
In this study, difference between control 
group (II) and subjects with breast cancer (I) 
was non-significant. Fibrinogen level was 
found to be significantly increased (p < 
0.01) in patients with different stages of 
breast cancer when compared with controls. 
This increased fibrinogen level may be due 
to pro-coagulant effect of tumor tissue. This 
study is in agreement with the findings of 
Laboratory 
Investigations 
cancer 
group 
(Mean) 
control 
group 
(Mean) 
cancer 
group 
(S.D) 
control 
group 
(S.D) 
Cancer group 
(Range) 
Control group 
(Range) 
General             
Hemoglobin 11.82 12.78 1.67 1.02 5.2 - 15.3 g/dl 11.5 - 14.3 g/dl 
Total Leucocyte count 7.34 7.91 2.15 1.46 3.4 – 13.3 x 109/L 4.5 – 10.2 x 109/L 
Platelet count 256.12 227.12 91.65 48.44 138 – 529 x 109/L 154 – 329 x 109/L 
Specific       
Prothrombin Time 14.20 12.80 1.30 1.27 12 -17 sec 11-15 sec 
Activated partial 
thromboplastin time 
25.90 24.80 2.29 1.38 21 - 32 sec 21 - 27 sec 
Fibrinogen Level 372.40 276.00 106.83 43.49 140 - 520 mg/dl 210 - 350 mg/dl 
Table 1: Comparison between special and specific hematological investigations between cancer and control group 
 
   
102 | A d v a n c e m e n t s  i n  L i f e  S c i e n c e s  V o l .  1 ,  I s s u e  2  
 
[15] who also observed these changes in 
breast cancer patients. FDPs were found to 
be significantly increased (p< 0.01) in 
patients of breast cancer when compared 
with control group. These increased levels 
of FDPs may be due to enhanced 
fibrinolysis. These findings are consistent 
with the results of many investigators, 
including [8,15,20]. They observed 
increased levels of FDPs in women with 
breast cancer.In this study, D-Dimers were 
found to be significantly increased (p < 
0.01) in patients with breast cancer when 
compared with controls. These increased 
levels of D-Dimers may be due to enhanced 
fibrinolysis. These findings are consistent 
with the results of [8,15]. They also 
observed similar increase of D-Dimers in 
different stages of breast cancer. Further 
case control and cohort studies are 
conducted on the same lines that may give 
helpful findings for the clinicians in early 
detection of breast cancer and DIC. Cohort 
studies in this regard better results for the 
research but they are to be costly as 
compared to case control studies. Early 
detection system for different disease could 
save number of years of life lost as in result 
of any disease related to genetic or cellular 
disorder [21, 22].  
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